OPEN LABEL TRIAL OF AZIMILIDE IN SUPRAVENTRICULAR ARRHYTHMIAS

杜克大学医学中心临床药理学和心脏病学部门的研究人员使用兰金临床研究单位研究了房颤和其他常见心律紊乱的患者。房颤是最常见的心律失常，需要抗心律失常药物治疗，占美国因心律失常住院治疗的三分之一以上。房颤患者通常的正常心律会被快速、不规则的心跳周期所取代，这可能会导致胸部剧烈跳动、呼吸急促、胸痛、头晕或意识丧失。这些时期可能持续几分钟或几个小时，也可能无限期持续，除非医生进行急性治疗。阿齐米利特是一种重要的研究III类抗心律失常药物，可阻断快慢内向钾通道。它被开发为一种治疗方法，用于减少患有心房颤动和/或心房扑动的患者出现症状性心律失常的频率。在D88方案中，成功完成阿齐米德随机、安慰剂对照临床试验的房颤患者每天服用开放标签阿奇米德75 mg或100 mg。随访已经完成，在该方案中没有进一步的患者接受随访。

Investigators in the Divisions of Clinical Pharmacology and Cardiology at Duke University Medical Center have used the Rankin Clinical Research Unit to study patients with atrial fibrillation and other common disorders of the heart rhythm. Atrial fibrillation is the most common disorder of the heart rhythm requiring treatment with antiarrhythmic drugs, and it accounts for over one-third of all U.S. hospitalizations for arrhythmias. Patients with atrial fibrillation have their usually normal heart rhythm replaced by periods of rapid, irregular heart beating that may cause a sense of pounding in the chest, shortness of breath, chest pain, dizziness, or loss of consciousness. These periods may last for minutes or hours, or they may last indefinitely unless acute treatment is given by a physician. Azimilide is an important investigational class III antiarrhythmic drug that blocks both rapid and slow inward potassium channels. It is being developed as a therapy to reduce the frequency of symptomatic arrhythmia occurrences in patients with atrial fibrillation, atrial flutter or both. In protocol D88 patients with atrial fibrillation who had successfully completed a randomized, placebo-controlled clinical trial of azimilide were treated with open-label azimilide75 mg or 100 mg daily. Follow-up has been completed, and no further patients are being followed in this protocol.